Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beauty Health (SKIN) Cash & Equivalents: 2020-2024

Historic Cash & Equivalents for Beauty Health (SKIN) over the last 5 years, with Dec 2024 value amounting to $370.1 million.

  • Beauty Health's Cash & Equivalents fell 38.87% to $219.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.4 million, marking a year-over-year decrease of 38.87%. This contributed to the annual value of $370.1 million for FY2024, which is 29.25% down from last year.
  • Latest data reveals that Beauty Health reported Cash & Equivalents of $370.1 million as of FY2024, which was down 29.25% from $523.0 million recorded in FY2023.
  • In the past 5 years, Beauty Health's Cash & Equivalents ranged from a high of $901.9 million in FY2021 and a low of $9.5 million during FY2020.
  • For the 3-year period, Beauty Health's Cash & Equivalents averaged around $487.1 million, with its median value being $523.0 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first spiked by 9,407.55% in 2021, then plummeted by 37.00% in 2022.
  • Beauty Health's Cash & Equivalents (Yearly) stood at $9.5 million in 2020, then spiked by 9,407.55% to $901.9 million in 2021, then slumped by 37.00% to $568.2 million in 2022, then declined by 7.95% to $523.0 million in 2023, then declined by 29.25% to $370.1 million in 2024.